The latest updated of drug registration lists on 07 July 2025.
No
Brand Name
Ingredients
Dosage Form
Primary Packaging
Indications
EDL
License Owner
Manufacturer
Country
Activity
Reg No.
Reg Date
Expiry Date
Action
1871
FUROCEF 500 MG CEFUROXIME AXETIL USP 609.7561 MG EQ.TO CEFUROXIME 500 MG
FILM COATED TABLET
ALU-ALU BLISTER PACK
PHARYNGITIS/TONSILLITIS, ACUTE BACTERIAL OTITIS MEDIA, ACUTE BACTERIAL MAXILLAR SINUSITIS, ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS AND SECONDARY BACTERIAL INFECTIONS OF ACUTE BRONCHITIS, UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTION, UNCOMPLICATED URINARY TRACT INFECTION, UNCOMPLICATED GONORRHEA, URETHRAL AND ENDOCERVICAL, EARLY LYME DISEASE
NULL
MEMESCO CO.,LTD
RENATA LIMITED
BANGLADESH
CERTIFICATE RELEASED
10 I 5621/23
17-OCT-2023
16-OCT-2026
View
1872
FUSTADIN CREAM 2% W/W FUSIDIC ACID 2% W/W
CREAM
TUBE
TREATMENT OF SKIN INFECTIONS CAUSED BY STAPHYLOCOCCI, STREPTOCOCCI, PROPIONIBACTERIUM ACNES, CORYNEBACTERIUM MINUTISSIMUM AND OTHER ORGANISM SENSITIVE TO FUSIDIC ACID: IMPETIGO, INFECTED WOUNDS, FOLLICULITIS, BOILS, SYCOSIS BARBAE, CARBUNCLES, HIDRADENITIS, PARONYCHIA, ERYTHRASMA
NULL
MEMESCO CO.,LTD
Y.S.P. INDUSTRIES (M) SDN.BHD
MALAYSIA
CERTIFICATE RELEASED
07 I 5576/23
07-JUL-2023
06-JUL-2026
View
1873
GABTIN 100 GABAPENTIN 100 MG
CAPSULE
PVC BLISTERPACK
USED AS MONOTHERAPY OR ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION, ALSO USED IN THE TREATMENT OF NEUROPATHIC PAIN.
NULL
MEMESCO CO.,LTD
ATLANTIC LABORATORIES CORPORATION LTD
THAILAND
CERTIFICATE RELEASED
04 I 5714/24
08-APR-2024
07-APR-2027
View
1874
GABTIN 300 GABAPENTIN 300 MG
CAPSULE
BLISTERPACK
USED AS MONOTHERAPY OR ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION, ALSO USED IN THE TREATMENT OF NEUROPATHIC PAIN.
NULL
MEMESCO CO.,LTD
ATLANTIC LABORATORIES CORPORATION LTD
THAILAND
CERTIFICATE RELEASED
04 I 5715/24
08-APR-2024
07-APR-2027
View
1875
GLIZID MR 30 MG GLICLAZIDE BP 30 MG
TABLET
ALU-PVC BLISTER
TYPE 2 DIABETE MELLITUS, WHEN DIET AND EXERCISE IS NOT SUFFICIENT TO OBTAIN NORMAL BLOOD GLUCOSE LEVEL
NULL
MEMESCO CO.,LTD
OPSONIN PHARMA LIMITED
BANGLADESH
CERTIFICATE RELEASED
06 I 4466/18
03-AUG-2022
02-AUG-2025
View
1876
GLUCOMET TABLET 500 MG METFORMIN HYDROCHLORIDE 500 MG
TABLET
ALU-PVC BLISTER
TREATMENT OF TYPE 2 DIABETES MELLITUS IN ADULT, WHEN DIETARY MANAGEMENT AND EXCERCISE ALONE DOES NOT RESULT IN ADEQUATE GLYCEMIC CONTROL
NULL
MEMESCO CO.,LTD
Y.S.P INDUSTRIES (M) SDN,BHD
MALAYSIA
CERTIFICATE RELEASED
02 I 5055/21
07-FEB-2024
06-FEB-2027
View
1877
LICONOR 300 MG URSODEOXYCHOLIC ACID BP 300 MG
TABLET
ALU-PVC BLISTER
TREATMENT OF CHOLESTASIS(JAUNDICE), ACUTE VIRAL HEPATITIS, VIRAL HEPATITIS, CHRONIC HEPATITIS C, ALCOHOLIC FATTY LIVER, PRIMARY BILLIARY CIRRHOSIS, PRIMARY SCLEROSING CHOLANGITIS, DISSOLUTION OF GALLSTONES AND NON-ALCOHOLIC STEATO HEPATITIS
NULL
MEMESCO CO.,LTD
OPSONIN PHARMA LIMITED
BANGLADESH
CERTIFICATE RELEASED
08 I 4536/18
03-AUG-2022
02-AUG-2025
View
1878
LORADINE LORATADINE 10MG
TABLET
ALU-PVC BLISTER
RELIEF OF SYMPTOMS ASSOCIATED WITH ALLERGIC RHINITIS E.G. SNEEZING, NASAL DISCHARGE AND ITCHING, AS WELL AS OCULAR ITCHING AND BURNING. CHRONIC URTICARIA AND OTHER ALLERGIC DERMATOLOGIC DISORDERS
NULL
MEMESCO CO.,LTD
Y.S.P. INDUSTRIES (M) SDN.BHD
MALAYSIA
CERTIFICATE RELEASED
06 I 3139/08
28-APR-2023
27-APR-2026
View
1879
LORADINE SYRUP 1MG/ML LORATADINE 1MG/ML
SYRUP
BOTTLE
RELIEF OF SYMPTOMS ASSOCIATED WITH ALLERGIC RHINITIS E.G. SNEEZING, NASAL DISCHARGE AND ITCHING, AS WELL AS OCULAR ITCHING AND BURNING. CHRONIC URTICARIA AND OTHER ALLERGIC DERMATOLOGIC DISORDERS
NULL
MEMESCO CO.,LTD
Y.S.P. INDUSTRIES (M) SDN.BHD
MALAYSIA
CERTIFICATE RELEASED
06 I 3134/08
28-APR-2023
27-APR-2026
View
1880
LORAMIDE LOPERAMIDE HCL 2MG
CAPSULE
ALU-PVC BLISTER
INDECATED FOR THE CONTROL AND SYMPTOMATIC RELIEF OF ACUTE NON-SPECIFIC DIARRHEA AND OF CHRONIC DIARRHEA ASSOCIATED WITH INFLAMATORY BOWEL DISEASE
NULL
MEMESCO CO.,LTD
Y.S.P. INDUSTRIES (M) SDN.BHD
MALAYSIA
CERTIFICATE RELEASED
03 I 2764/06
28-APR-2023
27-APR-2026
View
